AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06198660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy in addition to conventional therapy two sessions per week for 6 weeks
Study NCT06198660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy
Description: cognitive behavioral therapy in addition to conventional therapy two sessions per week for 6 weeks
Study NCT06198660 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy only
Description: conventional therapy two sessions for 6 weeks
Study NCT05092503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JINZHEN Granules for Oral Solution
Description: JINZHEN granules will be dissolved in drinking water and administered orally.
Study NCT05092503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules will be dissolved in drinking water and administered orally.
Study NCT06237907 — intervention group
Intervention type: OTHER
Intervention: Patients underwent lymphedema surgery
Description: Patients who have developed lymphedema and undergone lymphedema surgery.
Study NCT06237907 — intervention group
Intervention type: OTHER
Intervention: Patients underwent surgery without LVA
Description: For patients who have not experienced lymphedema but require surgery due to other disease such as cancer, trauma, chronic wounds, skin defects, etc.
Study NCT04799639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindilimab +paclitaxel+ cisplantin
Description: standard dose paclitaxel + cisplantin + Sindilimab every 3 weeks for 3 cycles
Study NCT05298969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporalis Myofascial flap
Description: Improvement of speech and feeding quality in patients with palatal defects by temporalis myofascial flap
Study NCT04345211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group1, walking group
Description: The walking group includes a weekly walking goal of 75 minutes.
Study NCT05495399 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patient received debulking surgery will be randomized to receive SBRT or conventional RT. SBRT means high dose per fraction compared to conventional RT.
Study NCT03238157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluocinolone Acetonide (FA) implant
Description: Fluocinolone Acetonide (FA) implant is designed to release FA at an initial rate of approximately 0.6 g/d, decreasing over the first month to a steady rate of 0.3 to 0.4 g/d with a duration of approximately 30 months.
Study NCT04704128 — intervention group
Intervention type: OTHER
Intervention: Salivic sample
Description: Collection of total saliva not stimulated
Study NCT05286385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1150 Sound Processor
Description: Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor
Study NCT05286385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1150 NF
Description: Speech perception tests whilst the subject is fitted with the CP1150 modified firmware (the addition of notch filters at 978Hz, 1956Hz, 2934Hz, 3912Hz).
Study NCT05286385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1150 + FF
Description: Speech perception tests whilst the subject is fitted with the CP1150 Sound Processor with ForwardFocus.
Study NCT05286385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CP1110
Description: Speech perception tests whilst the subject is fitted with the CP1110 Sound Processor.
Study NCT06000904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame-based balance training
Description: For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute balance exercise, and 15-minute ground walking as a cool-down.
Study NCT06000904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper limb and trunk training
Description: For a four-week intervention consisting of three weekly sessions, each lasting 60 minutes. Each training session will include a 5-minute warm-up activity, 40-minute upper-limb and trunk exercise, and 15-minute ground walking as a cool-down.
Study NCT06107686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL202 should be intravenously infused
Description: For each patient, YL202 should be intravenously infused over 60±10 min.
Study NCT06549127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Wearable Robot
Description: This study aims to enroll 20 participants who will receive assistance in flexion and extension of the knee and hip during overground walking adaptation training. Following the initial assessment, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered hip assistive device over two weeks. After completing these sessions, Post-intervention Assessment 1 will be conducted. Then, participants will undergo three 30-minute sessions of overground walking adaptation training with a powered knee assistive device over two weeks, followed by Post-intervention Assessment 2. Each participant will have a total of nine visits, including three functional assessments and six adaptation training sessions. The first visit will involve scheduling subsequent visits. The familiarization process will occur two to three times per week, adjustable for participants' convenience, with each set of three visits completed within three weeks.
Study NCT04895358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Intravenous (IV) infusion
Study NCT04895358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV infusion
Study NCT04895358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: IV infusion
Study NCT04895358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion
Study NCT04895358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: IV infusion
Study NCT04895358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin
Description: IV infusion
Study NCT04895358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liposomal doxorubicin
Description: IV infusion
Study NCT04895358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: oral administration
Study NCT04895358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: oral administration
Study NCT04895358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: IV infusion
Study NCT04895358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dextrose
Description: IV infusion
Study NCT04345211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2, Walking plus manual therapy
Description: Walking plus self-administered thorax manual therapy
Study NCT04345211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 3; Walking plus exercises with Theraband
Description: Walking plus thorax exercises with Theraband
Study NCT05599217 — intervention group
Intervention type: OTHER
Intervention: Dietary and nutritional questionnaire
Description: Nutrition assessment, nutrient intake, dietary inflammatory index, and frailty status will be examined using questionnaires.
Study NCT05599217 — intervention group
Intervention type: OTHER
Intervention: Neurological function, cognitive function, and life quality assessment
Description: Neurological function, cognitive function, and life quality will be examined using Glasgow Coma Scale, Modified Rankin Scale, Markwalder Grade Scale, Mini-mental state examination, and EuroQol five dimensions questionnaire.
Study NCT05599217 — intervention group
Intervention type: OTHER
Intervention: Peripheral blood test
Description: Collect peripheral blood samples from patients.
Study NCT05599217 — intervention group
Intervention type: OTHER
Intervention: Metabonomic test
Description: Collect urine and stool samples from patients.
Study NCT05599217 — intervention group
Intervention type: OTHER
Intervention: Hematoma test
Description: Collect hematoma fluid, dura mater, and hematoma outer membrane samples from patients.
Study NCT05373836 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: prognostic nutritional index calculated from laboratory parameters
Description: Calculated nutritional index using laboratory results of serum albumin, lymphocyte count, and cholesterol
Study NCT04829214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-313
Description: Single intratympanic injection
Study NCT04829214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection
Study NCT05737693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Week-long exposure therapy with ketamine infusion on day 2 and 4 of the psychotherapy
Study NCT05737693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Week-long exposure therapy with midazolam infusion on day 2 and 4 of the psychotherapy
Study NCT05315583 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of biological samples
Description: All participants will have at each of the visits: a venipuncture sample of 2 dry tubes of 7 mL to make up 3 aliquots and a nasopharyngeal swab (optional). The aliquots of serum / plasma and the nasopharyngeal swab will be stored at -80°C until sent to the Pasteur Institute.
Study NCT06074523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Measurement and self-report
Description: Measurements of behavioral performance and self-report
Study NCT04826614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: optimized treatment
Description: early adjust dose or change drug
Study NCT04826614 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: optimized treatment
Description: early adjust dose or change drug
Study NCT05598307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium bolus followed by normal saline infusion
Description: a bolus dose of magnesium will be followed by normal saline infusion
Study NCT05598307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium bolus followed by magnesium infusion
Description: a bolus dose of magnesium will be followed by a magnesium infusion
Study NCT05598307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline bolus followed by normal saline infusion
Description: a bolus of normal saline will be followed by normal saline infusion
Study NCT06628271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Guidelines
Description: Participant with typical spells will be investigated according to our guidelines. These include that participants with heredity for or signs and symptoms of cardiac disease will be subjected to an ECG and participants with two or more spells should be subjected to blood tests for anemia and iron deficiency
Study NCT06433232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROOT CANAL TREATMENT
Description: ROOT CANAL TREATMENT
Study NCT06433232 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ROOT CANAL TREATMENT
Description: ROOT CANAL TREATMENT
Study NCT05616780 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physiological test
Description: Lung volume measurements will be obtained using nitrogen washout and body plethysmography
Study NCT06305962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-RAD204
Description: 177Lu-RAD204 administered at Imaging (im) and Treatment (tr) doses
Study NCT05682573 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: hospitalized patient
Description: Collect the patient's whole blood for testing
Study NCT06273865 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Several assays
Description: Standard blood draw by venipuncture is performed in all study participants to collect blood samples in four 2.7 mL citrated blood tubes. Tube one is a dummy tube and is discarded. Tube two is used for the FVIII activity and thrombin generation assay on the EnzySystem. Tube three is used to perform conventional FVIII activity and thrombin generation assays. Tube four is used for duplicate measurements of the conventional assays and measurement of prothrombin F1+2 antigen levels, ADAMTS13 activity, FVIII antigen, VWF (von Willebrand Factor) antigen and von Willebrand ristocetin cofactor activity levels.
Study NCT03070132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm
Study NCT03070132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study NCT06032975 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: The PROFFIT questionnaire is a PRO instrument composed by 16 items encompassing all the major life domains where FT can be expressed and is formed by two type of items: (1) outcome (items 1-7) and (2) determinants (items 8-16); EORTC QLQ-C30 questionnaire (items 29-30) and OV28 (items 55-58); PRO-CTCAE: short list of 43 symptoms relevant for ovarian cancer
Study NCT05347953 — intervention group
Intervention type: DEVICE
Intervention: Single night downgraded home polygraphy
Description: All patients will be outfitted with the ambulatory downgraded polygraphy device (Nox A1, Nox Medical Global, Reykjavik) for 24 hour monitoring. The data exported by the polygraphy device is in European Data Format and will be filtered and annotated using custom MATLAB-software.
Study NCT06372483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VMX-C001
Description: VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs
Study NCT06372483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: VMX-C001 matched placebo
Study NCT06372483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rivaroxaban 20 mg Oral Tablet
Description: Fxa DOAC
Study NCT06372483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg Oral Tablet
Description: Fxa DOAC
Study NCT06372483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apixaban 5 mg Oral Tablet
Description: Fxa DOAC
Study NCT06372483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg Oral Tablet
Description: Fxa DOAC
Study NCT06372483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Edoxaban 60 mg Oral Tablet
Description: Fxa DOAC
Study NCT06372483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg Oral Tablet
Description: Fxa DOAC
Study NCT06547359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obicetrapib 10mg
Description: tablets
Study NCT06547359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: tablets
Study NCT05922098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Texture Modified Foods Manual for chewing dysfunctions in older adult
Description: Texture Modified Foods Manual for chewing dysfunctions (including IDDSI)
Study NCT06059001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMO-103
Description: Investigational Product: 35 mg/mL (4.5 mL/vial) concentrate for solution for infusion
Study NCT06059001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: IV infusion - Standard of Care
Study NCT06059001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion - Standard of Care
Study NCT05304962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT-419B
Description: oral capsules
Study NCT05304962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT-419B in combination with hormonal therapy
Description: RGT-419B in combination with hormonal therapy (Selective Estrogen Receptor Degrader, Selective Estrogen Receptor Modulator, or Aromatase Inhibitor)
Study NCT06451770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VERVE-201
Description: Intravenous (IV) infusion
Study NCT05703256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amygdala real-time fMRI neurofeedback
Description: Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
Study NCT05703256 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham feedback
Description: Participants are shown activity from another participant's left amygdala who previously completed the task and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
Study NCT04220190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAPA-501 Autologous T cells
Description: TREG/Th2 cells
Study NCT05861180 — intervention group
Intervention type: DEVICE
Intervention: inclinometer, smart phone goniometer and laser beam
Description: devices to objectively assess proprioception of the neck
Study NCT06497036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP404141
Description: subcutaneous injection
Study NCT05181475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Oligomannate Capsules (GV-971)
Description: Sodium Oligomannate Capsules, each capsule contains 150 mg of sodium oligomannate. The recommended treatment is oral administration, 450 mg (3 capsules) per dose, bid, in morning and evening.
Study NCT06446778 — intervention group
Intervention type: DEVICE
Intervention: Pipeline embolization device with or without shield technique
Description: The patients undenwent Pipeline embolization device implantation with or without shield technique due to market availability, choice and preferences of the surgeon.
Study NCT06568536 — intervention group
Intervention type: OTHER
Intervention: Repeated behavioral assessments, functional electroencephalography and brain imagery, TMS-EEG
Description: The presence of consciousness will be classified considering the highest level of consciousness revealed by repeated behavioral examinations, functional electroencephalography (task-based EEG), and functional brain imagery (task-based fMRI). Based on the results of this composite standard reference, we will evaluate the diagnostic and prognostic accuracy of TMS-EEG measurements of brain complexity
Study NCT06497036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nplate
Description: subcutaneous injection
Study NCT06007248 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Protocol-defined Examinations
Description: Lab tests (blood and urine and stool routine tests, hepatic and renal and thyroid function tests, tests for metabolic markers, tests for cardiac biomarkers, thrombosis-related tests, rheumatology tests, tests for inflammation markers), electrocardiography, echocardiography, Birmingham Vasculitis Activity Score (BVAS-3), 6-minute walk test, 1-minute squat test, vascular ultrasound, fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT), coronary angiography, optical coherence tomography (OCT), tests for exploratory biomarkers.
Study NCT05965466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal gastrectomy and radical resection
Description: Distal gastrectomy and Roux-en-Y anastomosis
Study NCT05965466 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Total gastrectomy and radical resection
Description: Total gastrectomy and Roux-en-Y anastomosis
Study NCT05432960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Study NCT05432960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution)
Study NCT06083493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFUP excitation
Description: The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-excitation) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.
Study NCT06083493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIFUP inhibition
Description: The experimental will consist of a 10-minute baseline period (LIFUP-OFF) followed by four 10-minute sessions of stimulating (LIFUP-ON-inhibition) four thalamic areas. The order of thalamic area stimulation will be counterbalanced across participants and will include the ventral anterior (VA), dorsal anterior (DA), ventral posterior (VP), and dorsal posterior (DP) sections of the thalamus.
Study NCT04702672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% wheat (control)
Description: Intake of 250 ml of tap water and 100 g of bread baked with 100% wheat flour (regular commercial available wheat flour). Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.
Study NCT04702672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100% Lean-baking barley®
Description: Intake of 250 ml of tap water and 100 g of bread baked with 100% Lean-baking barley® flour. Consumed over maximum 10 minutes at time 0 min after overnight fasting. At one of four visits.~HIAMBA® are naturally bred in corporation with PlantCarb ApS and researchers at Aarhus and Copenhagen Universities. The wheat flour is standard commercial available flou